Neuroendocrine Tumors: Challenges and Future Perspectives
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".
Deadline for manuscript submissions: closed (20 August 2023) | Viewed by 22894
Special Issue Editors
Interests: neuroendocrine tumors; drug development; clinical research; translational research; precision oncology
Special Issues, Collections and Topics in MDPI journals
Interests: neuroendocrine tumors; small-cell lung cancer; immunotherapy; clinical research; precision oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Neuroendocrine tumors (NETs) are a family of neoplasms of increasing incidence and prevalence worldwide. Their heterogeneity in terms of biological aggressiveness, their variegated site of origin (although they are most commonly gastro-entero-pancreatic in about 60% of cases and pulmonary in approximately 30% of cases) and their capability to potentially produce hormonally active substances poses unique challenges for clinical management. NETs are characterized by the peculiar and frequent expression on cell surfaces of somatostatin receptors, which represents the ideal target for therapy (i.e., somatostatin analogues (SSAs) and peptide-receptor radionuclide therapy (PRRT)). Few chemotherapy schemes (such as streptozotocin/5-FU or the association of Capecitabine and Temozolomide) are currently part of the therapeutic armamentarium. However, regardless of the huge number of clinical trials and many promising new drugs, the only approved targeted agents for advanced progressive NETs are everolimus and sunitinib (the second one only for those of pancreatic origin). Additionally, despite a great effort in the search for innovative biomarkers, only few validated biomarkers are available so far. The aim of this Special Issue is to highlight recent advances in the context of diagnosis, treatment, and the prediction of prognosis for NETs.
Dr. Anna La Salvia
Dr. Giuseppe Lamberti
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neuroendocrine tumors
- clinical challenges
- innovative biomarkers
- novel agents
- personalized oncology